Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.

Kyeyune F, Nankya I, Metha S, Akao J, Ndashimye E, Tebit DM, Rodriguez B, Kityo C, Salata RA, Mugyenyi P, Arts E; JCRC Drug Resistance Working Group.

AIDS. 2013 Jul 31;27(12):1899-909.

PMID:
23727942
[PubMed - indexed for MEDLINE]
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
3.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
[PubMed - indexed for MEDLINE]
4.

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.

Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502.

PMID:
19331585
[PubMed - indexed for MEDLINE]
Free Article
5.

Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.

Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RS, Chequer-Fernandez SL, Oliveira SM, Arakaki-Sanchez D, Chequer PJ, Morgado MG.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):73-8. Epub 2005 Apr 12.

PMID:
15867968
[PubMed - indexed for MEDLINE]
Free Article
6.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme.

Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81.

PMID:
23031662
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group.

Antivir Ther. 2009;14(3):359-69.

PMID:
19474470
[PubMed - indexed for MEDLINE]
8.

Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.

Zolfo M, Schapiro JM, Phan V, Koole O, Thai S, Vekemans M, Fransen K, Lynen L.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):727-35. doi: 10.1089/AID.2010.0037. Epub 2010 Nov 23.

PMID:
20854169
[PubMed - indexed for MEDLINE]
9.

High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.

Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugyenyi P, Arts EJ.

AIDS Res Hum Retroviruses. 2004 Apr;20(4):355-64.

PMID:
15157354
[PubMed - indexed for MEDLINE]
10.

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.

Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, Moore RD, Bates M, Quinn TC.

Clin Infect Dis. 2006 Jan 15;42(2):252-9. Epub 2005 Dec 12.

PMID:
16355337
[PubMed - indexed for MEDLINE]
Free Article
11.

Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.

Weidle PJ, Downing R, Sozi C, Mwebaze R, Rukundo G, Malamba S, Respess R, Hertogs K, Larder B, Ochola D, Mermin J, Samb B, Lackritz E.

AIDS. 2003 Jul;17 Suppl 3:S39-48.

PMID:
14565608
[PubMed - indexed for MEDLINE]
12.

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

Bratt G, Karlsson A, Leandersson AC, Albert J, Wahren B, Sandström E.

AIDS. 1998 Nov 12;12(16):2193-202.

PMID:
9833861
[PubMed - indexed for MEDLINE]
13.

The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa.

Ataher Q, Portsmouth S, Napolitano LA, Eng S, Greenacre A, Kambugu A, Wood R, Badal-Faesen S, Tressler R.

J Int AIDS Soc. 2012 Jan 26;15(1):2. doi: 10.1186/1758-2652-15-2.

PMID:
22281097
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L.

AIDS Res Hum Retroviruses. 2008 Nov;24(11):1449-54. doi: 10.1089/aid.2008.0180.

PMID:
19000027
[PubMed - indexed for MEDLINE]
15.

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W.

Curr HIV Res. 2008 Sep;6(5):474-6.

PMID:
18855659
[PubMed - indexed for MEDLINE]
16.

High frequency of antiviral drug resistance and non-B subtypes in HIV-1 patients failing antiviral therapy in Cuba.

Kourí V, Alemán Y, Pérez L, Pérez J, Fonseca C, Correa C, Aragonés C, Campos J, Álvarez D, Schrooten Y, Dekeersmaeker N, Imbrechts S, Beheydt G, Vinken L, Pérez D, Álvarez A, Soto Y, Vandamme AM, Van Laethem K.

J Clin Virol. 2012 Dec;55(4):348-55. doi: 10.1016/j.jcv.2012.08.019. Epub 2012 Sep 13.

PMID:
22981617
[PubMed - indexed for MEDLINE]
17.

Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.

Al Hajjar SH, Frayha H, Althawadi S.

Ann Saudi Med. 2012 Nov-Dec;32(6):565-9. doi: 10.5144/0256-4947.2012.565.

PMID:
23396017
[PubMed - indexed for MEDLINE]
18.

Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.

Towler WI, Barlow-Mosha L, Church JD, Bagenda D, Ajuna P, Mubiru M, Musoke P, Eshleman SH.

AIDS Res Hum Retroviruses. 2010 May;26(5):563-8. doi: 10.1089/aid.2009.0164.

PMID:
20455758
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.

de Mulder M, Yebra G, Navas A, Martin L, de Jose MI, Navarro ML, de Ory SJ, Gonzalez-Granado I, Mellado MJ, Ramos JT, Holguin A.

Pediatr Infect Dis J. 2012 Nov;31(11):e213-21. doi: 10.1097/INF.0b013e3182678c7c.

PMID:
22785049
[PubMed - indexed for MEDLINE]
20.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

PMID:
23044036
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk